Honest Criticisms and Limitations of the SURMOUNT-1 Trial
A clinical-research deep dive into the real methodological limitations, enrollment biases, generalizability gaps, and statistical caveats of the SURMOUNT-1 tirzepatide weight-loss trial.
Trials Surmount 1
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
May 25, 2026latest review
Trials Surmount 1 library
Showing 8 of 8 clinical reviews.
Inside the SURMOUNT-1 Methodology: What Most Summaries Skip
A detailed breakdown of SURMOUNT-1's randomization, blinding, estimand framework, and statistical design, and why each methodological choice matters for interpreting tirzepatide's 20.9% weight-loss result.
SURMOUNT-1 Cost, Cost-Effectiveness, and Health-Economic Implications
A deep dive into cost-per-QALY models, payer-coverage realities, and individual value calculations built on SURMOUNT-1 tirzepatide trial data.
SURMOUNT-1 Extension Data and What Happened After the Trial Ended
Deep-dive into SURMOUNT-1 follow-up and extension findings for tirzepatide, covering weight regain after discontinuation, durability of cardiometabolic benefits, and emerging long-term safety signals.
SURMOUNT-1 Results in Detail: Numbers, Subgroups, and Time Course
A deep dive into the SURMOUNT-1 trial results for tirzepatide 5, 10, and 15 mg, covering primary and secondary endpoints, confidence intervals, weight-loss time course, and response distribution data beyond the abstract.
SURMOUNT-1 Subgroup Analyses: Who Responded Most and Least to Tirzepatide
Deep-dive into SURMOUNT-1 pre-specified and post-hoc subgroup analyses by age, sex, BMI, race, and baseline biomarkers, revealing which patients responded most to tirzepatide for weight loss.
SURMOUNT-1 Trial: A Plain-English Overview of What It Established
A plain-English deep dive into the SURMOUNT-1 trial, explaining how tirzepatide achieved up to 20.9% weight loss in adults with obesity and what that means for clinical practice.
What SURMOUNT-1 Actually Changes in Clinical Practice
A clinical-practice translation of the SURMOUNT-1 trial: which guidelines updated after tirzepatide showed 20.9% weight loss, which prescribing patterns shifted, and what the data mean for patients who differ from the trial population.